![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Antiviral Activity of ABT-267, a Novel NS5A Inhibitor, During 3-Day Monotherapy:
First Study in HCV Genotype-1 (GT1)-Infected Treatment-Naïve Subjects
|
|
|
Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
Eric Lawitz1, Thomas Marbury2, Andrew Campbell3, Emily Dumas3, Tami Pilot-Matias3, Preethi Krishnan3, Carolyn Setze3, Wangang Xie3, Thomas Podsadecki3, Barry Bernstein3, Laura Williams3
1Alamo Medical Research, San Antonio, Texas, United States; 2Orlando Clinical Research Center, Orlando, Florida, United States; 3Abbott, Abbott Park, Illinois, United States
![EASL1.gif](../images/042512/042512-9/EASL1.gif)
![EASL2.gif](../images/042512/042512-9/EASL2.gif)
![EASL3.gif](../images/042512/042512-9/EASL3.gif)
![EASL4.gif](../images/042512/042512-9/EASL4.gif)
![EASL5.gif](../images/042512/042512-9/EASL5.gif)
![EASL6.gif](../images/042512/042512-9/EASL6.gif)
![EASL7.gif](../images/042512/042512-9/EASL7.gif)
![EASL8.gif](../images/042512/042512-9/EASL8.gif)
![EASL9.gif](../images/042512/042512-9/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|